This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why Elbit Imaging (EMITF) Is Soaring on Tuesday

NEW YORK (TheStreet) -- Elbit Imaging (EMITF) is rocketing higher on Tuesday after announcing  Gamida Cell Ltd, which Elbit's subsidiary Elbit Medical Technologies holds 30.8% voting power in, had received an acquisition proposal from a pharmaceutical company.

By midafternoon, Elbit Imaging shares had climbed 37.3% to 28 cents. Trading volume of 8.4 million was nearly nine times higher than its three-month daily average.

"The proposed consideration for such purchase is expected to include a payment of a significant amount upon closing, as well as certain milestone-based payments (contingent upon development, regulatory approvals or sales related to Gamida Cell's product), with such proposed consideration expected to amount to up to several hundred million dollars," the company said in a statement.

The Israel-based business said no definitive agreement had been signed nor did it disclose which global pharmaceutical company had made the offer.

Must Read: Why Gulf Resources (GURE) Hit a One-Year High Today

Elbit Imaging holds 86% voting power in Elbit Medical Technologies.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

EMITF Chart EMITF data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
EMITF $1.09 2.83%
AAPL $117.82 -0.18%
FB $105.19 -0.21%
GOOG $750.34 0.29%
YHOO $32.79 -1.10%


Chart of I:DJI
DOW 17,806.58 -6.81 -0.04%
S&P 500 2,089.02 +0.15 0.01%
NASDAQ 5,119.70 +3.5570 0.07%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs